Clinical Trial Update: Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Necitumumab with gemcitabine as neoadjuvant therapy in surgically resectable squamous cell lung cancer; study terminated with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Cancer

Drugs mentioned

• Necitumumab (necitumumab)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Squamous Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-02-18